No retraction, correction or concern found when last checked on Oct 31, 2026.

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Piyada Supasa, Daming Zhou, Wanwisa Dejnirattisai and 50 more

Cell · 2021 · CC BY

doi:10.1016/j.cell.2021.02.033

Abstract

SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being deployed at scale, aiming to generate responses against the virus spike. The scale of the pandemic and error-prone virus replication is leading to the appearance of mutant viruses and potentially escape from antibody responses. Variant B.1.1.7, now dominant in the UK, with increased transmission, harbors 9 amino acid changes in the spike, including N501Y in the ACE2 interacting surface. We examine the ability of B.1.1.7 to evade antibody responses elicited by natural SARS-CoV-2 infection or vaccination. We map the impact of N501Y by structure/function analysis of a large panel of well-characterized monoclonal antibodies. B.1.1.7 is harder to neutralize than parental virus, compromising neutralization by some members of a major class of public antibodies through light-chain contacts with residue 501. However, widespread escape from monoclonal antibodies or antibody responses generated by natural infection or vaccination was not observed.

References 60

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
Phaser crystallographic software · 2007
No notice
11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
12.
DIALS : implementation and evaluation of a new integration package · 2018
No notice
13.
Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix · 2019
No notice
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV · 2020
Corrected
16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies · 2020
No notice
19.
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike · 2020
Corrected
20.
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 · 2020
No notice
21.
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies · 2020
No notice
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
Structural basis of a shared antibody response to SARS-CoV-2 · 2020
No notice
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
26.
Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy · 2020
No notice
27.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
28.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
29.
Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding · 2020
No notice
30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
31.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
32.
An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain · 2020
No notice
33.
Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans · 2021
No notice
34.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
35.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
36.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK · 2021
Corrected
37.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
38.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
39.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
40.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

All 60 references

Cited by papers we hold 19

Cooperative multivalent receptor binding promotes exposure of the SARS-CoV-2 fusion machinery core · 2022
Not checked
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines · 2022
No notice
SARS-COV-2 Variants: Differences and Potential of Immune Evasion · 2022
No notice
Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies · 2022
No notice
A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations · 2022
No notice
COVID-19 vaccine development: milestones, lessons and prospects · 2022
No notice
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines · 2022
No notice
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis · 2022
No notice
Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants · 2022
No notice
SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape · 2022
No notice
Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2 · 2021
Not checked
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine · 2021
No notice
Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics · 2021
No notice
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination · 2021
No notice
Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far? · 2021
No notice
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 · 2021
No notice
A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics · 2021
No notice
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant · 2021
No notice
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose · 2021
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.